Matt Berman

Principal

Indianapolis, IN, US

Matt Berman is principal in the Indianapolis Health Practice and leads the team that provides Market Access Strategy and Agency of Record Services to life science companies. He joined the firm in 2009.

Download bio

Loading component...

Experience

Matt has more than 10 years of experience supporting life science companies in market access strategy. Project work includes the following general areas:

Launch strategy market - access focused
Access stakeholder engagement strategy
Market segmentation
Account director training
Access platform tactical development:
- Evidence generation | PIE presentations | Payer value propositions | Budget impact tools | Design of novel training programs | Implementation guidance
Pull through program design and execution
- Internal communication and process design | Field-oriented goal setting | Veeva-enabled dynamic pull through messaging | Omni-channel messaging
Patient journey mapping
Access landscape development
Specialty pharmacy strategy
Patient support and hub design
Pricing
Contracting

Presentations and publications

Berman, M. & Lain, S. "Diabetes burden on population groups: Research summary." July 2019.
Berman, M. Lain, S., & Metz, L. "Mitigating out-of-pocket costs for insulin users." May 2019.
Berman, M. & Jackson. A. "Mitigating out-of-pocket costs for prescription drugs." March 2017.
Berman, M. "Pull-through capabilities: Communicating effectively with prescribers about cost and coverage." February 2014.

Professional Designations

Education

MBA, Kelley School of Business, Indiana University

Publications

Read their latest work

Article

Applying Six Sigma principles to the Medicare Prescription Payment Plan: 5 patient-centered process improvements to maximize value for older adults

17 February 2026 - by Matt Berman, Rachel Crum, Rhea D'Silva, Corinne Owens, Jon Yalcin

How can healthcare stakeholders use Six Sigma to transform the Medicare Prescription Payment Plan into a widely adopted and trusted benefit?

Article

Navigating national priority vouchers: Three critical shifts affecting strategy for life sciences companies and payers

03 December 2025 - by Matt Berman, Chris Page, Chad Barker, Corinne Owens

We discuss three critical shifts for life sciences companies to consider in the wake of the FDA’s new structure for approval timelines for selected products.

Article

Beneficiary considerations for the Medicare Prescription Payment Plan

18 November 2024 - by Matt Berman, Adam Feller, Chad Barker, Jacob Hahn

We explore the Medicare Prescription Payment Plan's benefits and challenges for beneficiaries, emphasizing the need for clear communication and education to enhance understanding and decision-making.

Article

FTC pharmacy benefit management transparency report: How might pharma evaluate transparency reform impacts to drug channel stakeholders?

04 September 2024 - by Chad Barker, Chris Page, Matt Berman

In the wake of the FTC’s recent transparency report on pharmacy benefit managers, we look at how reform might impact drug channel stakeholders.

Article

The Inflation Reduction Act passed, now what?

30 September 2022 - by AJ Ally, Matt Berman, Michelle (Klein) Robb, Kevin Pierce

Drug manufacturers should take the time now to understand how the Inflation Reduction Act will affect Medicare and carefully plan.

Article

Insulin legislative changes: Current proposals and road map

13 July 2022 - by Matt Berman, Kevin Pierce

We examine various Congressional proposals that would affect insulin, including potential impacts on stakeholders and downstream health equity implications.

Article

Potential policy changes that could upend prescription drug pricing

16 April 2022 - by AJ Ally, Matt Berman

We discuss three primary targets to reduce prescription drug costs in the U.S., with potentially substantial changes in pricing for Medicare Parts B and D.

Article

Diabetes burden on population groups: Research summary

22 July 2019 - by Matt Berman, Scott Lain

This report provides data on the burden of diabetes on various subsets of the U.S. population.

Article

Mitigating out-of-pocket costs for insulin users

30 May 2019 - by Matt Berman, Scott Lain, Luke Metz

This report identifies potential approaches that plan administrators could take in an effort to reduce out-of-pocket costs for insulin-taking members.

Article

Mitigating out-of-pocket costs for prescription drugs

27 March 2017 - by Matt Berman, Elizabeth Anne Jackson

This analysis identifies tactics plan administrators could adopt that would reduce out-of-pocket costs for brand-name drugs.

Matt Berman

Loading component...

Experience

Presentations and publications

Read their latest work

Applying Six Sigma principles to the Medicare Prescription Payment Plan: 5 patient-centered process improvements to maximize value for older adults

Navigating national priority vouchers: Three critical shifts affecting strategy for life sciences companies and payers

Beneficiary considerations for the Medicare Prescription Payment Plan

FTC pharmacy benefit management transparency report: How might pharma evaluate transparency reform impacts to drug channel stakeholders?

The Inflation Reduction Act passed, now what?

Insulin legislative changes: Current proposals and road map

Potential policy changes that could upend prescription drug pricing

Diabetes burden on population groups: Research summary

Mitigating out-of-pocket costs for insulin users

Mitigating out-of-pocket costs for prescription drugs

Loading component...

CHOOSE A LOCATION AND LANGUAGE

Matt Berman

Read their latest work

Applying Six Sigma principles to the Medicare Prescription Payment Plan: 5 patient-centered process improvements to maximize value for older adults

Navigating national priority vouchers: Three critical shifts affecting strategy for life sciences companies and payers

Beneficiary considerations for the Medicare Prescription Payment Plan

FTC pharmacy benefit management transparency report: How might pharma evaluate transparency reform impacts to drug channel stakeholders?

The Inflation Reduction Act passed, now what?

Insulin legislative changes: Current proposals and road map

Potential policy changes that could upend prescription drug pricing

Diabetes burden on population groups: Research summary

Mitigating out-of-pocket costs for insulin users

Mitigating out-of-pocket costs for prescription drugs

CHOOSE A LOCATION AND LANGUAGE